Pfizer Reports the P-III (ECHELON-3) Trial Results of Adcetris for Treating R/R Diffuse Large B-cell Lymphoma (DLBCL)
Shots:
- The P-III (ECHELON-3) trial assesses Adcetris + lenalidomide and rituximab vs PBO + lenalidomide and rituximab in r/r DLBCL patients (n=230), irrespective of CD30 expression, previously treated with 2 or more lines of therapy and are not eligible for stem cell transplant or CAR-T therapy
- The study demonstrated a 37% reduction in death risk, mOS of 13.8mos. vs 8.5mos., mPFS of 4.2mos. vs 2.6mos., ORR of 64.3% vs 41.5% and CR rate of 40.2% vs 18.6%
- The safety results showed grade 3 or higher TEAEs of neutropenia (43% vs 28%), thrombocytopenia (25% vs 19%) and anemia (22% vs 21%) with low-grade & infrequent peripheral sensory neuropathy and 4% vs 0% grade 3 events
Ref: Pfizer | Image: Pfizer
Related News:- Pfizer Reports P-III Study Results of Adcetris for Treating Diffuse Large B-cell Lymphoma (DLBCL)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
